2022
DOI: 10.1016/s2666-6367(22)00343-8
|View full text |Cite
|
Sign up to set email alerts
|

Safety and Efficacy of Dose Escalation of Defibrotide in Hematopoietic Stem Cell Transplantation (HSCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Refractory to Standard Doses of Defibrotide

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles